Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2011

View Archived Issues

QLT reports promising phase II data on L-PPDS in glaucoma

Bristol-Myers Squibb small-molecule MAP kinase p38 alpha inhibitor shows promise to treat arthritis

Pfizer describes discovery and investigation of AMPA receptor modulator now in phase I

Additional analyses of AVERROES study presented

Daewoong Pharmaceutical discloses new antifungal agents

Novel plant extracts prepared by German researchers

Hanmi Holdings presents new epidermal growth factor receptor inhibitors

Nanoemulsion-based RSV vaccine achieves durable viral clearance in vivo

GSK synthesizes novel interferon inducers

N30 Pharmaceuticals patents new alcohol dehydrogenase class-3 inhibitors

U.S. universities claim novel serotonin 5-HT2C receptor agonists

Boehringer Ingelheim begins new afatinib trials in breast cancer

Stellar Biotechnologies receives National Science Foundation grant

Talon Therapeutics and FDA reach agreement on HALLMARQ trial

Novartis seeks Japanese approval of tobramycin

Pharming returns certain Ruconest marketing rights to Swedish Orphan Biovitrum

Immuron to begin clinical testing of influenza product

Ipsen and Inspiration Biopharmaceuticals sign European partnership agreement in hemophilia

FDA grants fast track status to letermovir

Brain-penetrant inhibitor of kynurenine aminotransferase II described by Pfizer

Adimab announces new collaborations

FDA clears new anti-CCP assay for diagnosis of rheumatoid arthritis

NuPathe receives FDA complete response letter regarding Zelrix NDA

FDA accepts Relistor sNDA for filing

Cyclacel announces initiation of phase II trial of sapacitabine capsules

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 1, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026